^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + eprenetapopt (APR-246) (p53 reactivator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
516MO - Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies
Published date:
09/13/2021
Excerpt:
Two pts with TP53 mutant NSCLC who received prior anti-PD-1/PD-L1 therapy demonstrated reductions in target lesion size of 27% and 8.2%, respectively, at the first disease assessment….The combination of eprenetapopt and pembrolizumab is safe and tolerable. Early signals of anti-tumor activity are observed.
Trial ID:
